Gastrointestinal Cancer | Specialty

Dr. Zafar on the Potential of Immunotherapy in Colorectal Cancer

August 31st 2015

S. Yousuf Zafar, MD, associate professor of medicine, Duke Cancer Institute, discusses the potential of immunotherapy for the treatment of patients with colorectal cancer (CRC).

Precision Medicine Modeling Helps Advance Colorectal Cancer Care

August 30th 2015

Preclinical mouse models and cell lines link colorectal cancer subtypes subtypes with potential therapies.

New FIRE-3 Analysis Shows Importance of Subsequent Therapies on mCRC Outcomes

August 28th 2015

Sequence of therapies may be more significant versus single agents in treating patients with metastatic colorectal cancer.

JAK Inhibitors Used as Anti-inflammatory Therapeutics for Pancreatic Cancer

August 23rd 2015

Experts review ongoing clinical research with JAK inhibitors in advanced pancreatic cancer as well as some strategies for preclinical testing of vertical inhibition of the JAK pathway.

Coffee May Reduce Colon Cancer Recurrence by Over 40%

August 21st 2015

Charles S. Fuchs, MD, discusses a recent study which found that consuming four or more cups of coffee per day may reduce risk of recurrence by 42% and death by 34% in patients with stage III colon cancer.

Shifting the Risk-Benefit Ratio in CRC With Molecular Subtyping

August 16th 2015

Recent evidence has shed some light on the prognostic value of microsatellite instability and the potential benefit of checkpoint inhibition in colorectal cancer.

PALB2 Mutations Confer Susceptibility to Familial Pancreatic Cancer and May Provide a Novel Targeted Therapeutic Approach to Cancer

August 15th 2015

Germline mutations in PALB2 have recently been shown to increase lifetime risk of pancreatic cancer and breast cancer, among other types.

Dr. Garcia-Carbonero on Quality of Life Impact of FOLFIRI Plus Ramucirumab in mCRC

August 7th 2015

Rocio Garcia-Carbonero, MD, PhD, Universidad de Sevilla, discusses the quality of life results from the RAISE study. The RAISE study was a phase III randomized, double-blind study of FOLFIRI plus ramucirumab or placebo in patients with metastatic colorectal cancer (mCRC) after first-line therapy with bevacizumab, oxaliplatin, or fluoropyrimidine.

PEGPH20 Shows Promise in HA-High Pancreatic Cancer

August 7th 2015

Andrew Hendifar, MD, discusses how PEGPH20 improved progression-free survival by 4.9 months in patients with advanced pancreatic cancer with high expression levels of hyaluronan.

Pembrolizumab Demonstrates Potential of Immunotherapy in Gastric Cancer

August 5th 2015

Yung-Jue Bang, MD, PhD, discusses how the results of the KEYNOTE-012 study demonstrate the potential of immunotherapy in treating gastric cancer.

More Aggressive Therapy Options Are on the Table for Elderly Patients With HCC

August 4th 2015

Pierre M. Gholam, MD, discusses managing elderly patients with advanced HCC, including current practices and emerging strategies.

Options in Unresectable Metastatic Colorectal Cancer

July 29th 2015

Initial Treatments for Newly Diagnosed Colorectal Cancer

July 29th 2015

Communicating Test Results to Patients

July 29th 2015

Mutation Analysis in Colorectal Cancer

July 29th 2015

Biopsy for Colorectal Cancer

July 29th 2015

Discussing Genetic Testing in Colorectal Cancer

July 29th 2015

Effective Communication in Colorectal Cancer

July 29th 2015

Optimizing the Treatment of Pancreatic Neuroendocrine Tumors

July 28th 2015

Combination and Sequential Treatment for pNETs

July 28th 2015